Compounds and methods for treating or reducing pruritus
View Patent ↗The present invention features methods and compositions for preventing, inhibiting, or reducing the sensation of itch (pruritus) by modulating the gene expression of TMEM184B. Modulating the gene expression of TMEM184B may comprise increasing Tmem184B protein expression, increasing Tmem184B protein activity or both. Furthermore, the methods and compositions described herein may activate the Tmem184B protein or activate a pathway leading to Tmem184B activation. Additionally, the methods and compositions for modulating the gene expression of TMEM184B may be used to help prevent or treat certain diseases or conditions such as dermatitis.
1 . A method of treating sensation of itch or pruritus in a subject in need thereof, said method comprising administering a compound comprising a recombinant TMEM184B or a nucleic acid vector encoding thereof to the subject to cause a reduction in the sensation of itch or pruritus.
2 . The method of claim 1 , wherein the compound is integrated into a pharmaceutically acceptable carrier.
3 . The method of claim 2 , wherein the pharmaceutically acceptable carrier is a lipid-based carrier, wherein the lipid-based carrier is a liposome.
4 . The method of claim 1 , wherein the sensation of itch is IL-31-induced itch.
5 . The method of claim 1 , wherein the method further treats dermatitis.
6 . A method of treating dermatitis in a subject in need thereof, said method comprising administering a compound comprising a recombinant TMEM184B or a nucleic acid vector encoding thereof to the subject to cause a reduction in dermatitis.
7 . The method of claim 6 , wherein the compound is integrated into a pharmaceutically acceptable carrier.
8 . The method of claim 7 , wherein the pharmaceutically acceptable carrier is a lipid-based carrier, wherein the lipid-based carrier is a liposome.